In an article recently published by PharmaTimes Online, Tillotts Pharma UK General Manager Jeremy Thorpe together with Chief Executive Richard Gardner from the British Society of Gastroenterology (BSG) explain the reason behind establishing the BSG-run Inflammatory Bowel Disease (IBD) Registry and how the Pharma Industry can help healthcare systems through effective collaboration.
For the last year, Tillotts Pharma UK, along with 4 other pharmaceutical companies, have been part of the IBD Registry Industry Working Group (IWG) run by the BSG. The purpose of the IBD Registry is to capture anonymised data from every IBD team in the UK and compare it with hospital data for prospective audit and research. To speed up the process of collecting the valuable data, the companies came together to provide the Registry with the needed data. The ultimate goal is to improve the outcome for patients suffering from IBD by gaining a better understanding of the disease.
According to the IBD Registry’s website, by bringing this data together for the first time, the aim is to:
To read the full article, click here